Baird upgraded Quest Diagnostics (DGX) to Outperform from Neutral with a price target of $182, up from $157. The firm likes the lab setup in 2025 and says “there’s no reason to hold back on one simply because the other is cheaper.” The lab sector trend is good and Quest has a host of catalysts to drive accelerating growth in 2025, the analyst tells investors in a research note. Baird says that with eight acquisitions closing in 2024, the company’s acquisition momentum carries into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Early notable gainers among liquid option names on October 22nd
- Morning Movers: 3M gains and GE Aerospace falls following third quarter results
- Quest Diagnostics narrows FY24 adjusted EPS view to $8.85-$8.95 from $8.80-$9.00
- Quest Diagnostics reports Q3 adjusted EPS $2.30, consensus $2.26
- Notable companies reporting before tomorrow’s open